
    
      The purpose of this study is to:

        -  assess the safety and efficacy of multiple dose levels of INS37217 compared to placebo
           over 28 days in subjects with mild to moderate CF lung disease;

        -  explore evidence of activity of INS37217 and placebo administered via PARI LC STAR
           nebulizer;

        -  identify dose(s) that will be studied in subsequent trials.
    
  